Piramal Pharma Share Price Target 2025: Will It Reach ₹300?

Piramal Pharma Share Price Target 2025: Will It Reach ₹300?

Piramal Pharma (NSE: PPLPHARMA) is currently trading in the ₹204–₹206 range as of August 1, 2025. With neutral RSI, mixed signals from moving averages, and resistance around ₹210, the stock appears to be in a consolidation phase. However, breakout potential remains alive for 2025, with analysts predicting a target range between ₹260 and ₹300 based on technical trends and pharma sector momentum.

Current Stock Highlights

Indicator Value
Current Price ₹190.50
52-Week High/Low ₹307.85 / ₹166.00
Market Cap ₹25.17KCr
Volume Stable / Low
Sector Pharma / CDMO

Piramal Pharma Share Price Chart

Technical Analysis (As of August 1, 2025)

  • RSI (Relative Strength Index): 50.41 → Neutral zone

  • MACD: +0.51 → Mildly bullish momentum

  • 20-Day EMA: ₹205.65 → Close to current price

  • 50-Day MA: ₹203.81 (Buy Signal)

  • 200-Day MA: ₹224.60 (Still below, indicating resistance)

  • Immediate Resistance: ₹210–₹212

  • Support Zone: ₹200–₹202

These indicators suggest the stock may be poised for a breakout, but needs strong volume confirmation.

Piramal Pharma Share Price Target 2025

Outlook Price Target (₹) Technical Condition
Bullish ₹280 – ₹300 Break above ₹210 with strong volume
Base Case ₹260 – ₹280 Sustained momentum with pharma tailwinds
Bearish ₹200 – ₹215 Rejection at ₹210, sector underperforms

Key Growth Drivers

  • CDMO Expansion: Strong growth in custom development and manufacturing contracts

  • Generics Business: Contribution from inhalation and injectable drugs

  • Hospital Solutions: Margin improvement potential

  • New Product Pipeline: Portfolio expansion in complex generics

Risks to Watch

  • High Valuation: Current P/E ~300x could limit fresh buying

  • Overhead Resistance: ₹210–₹212 needs strong breakout

  • Pharma Sector Regulation: Domestic and global compliance factors

  • Muted Volume: Lack of institutional interest in short term

Expert Opinion

According to analysts at Trendlyne and TipRanks, the next major trend will depend on earnings visibility and momentum above ₹210. If crossed, the stock can quickly aim for ₹260+ in the coming quarters.

Piramal Pharma looks technically neutral but fundamentally promising. Investors should watch the ₹210 resistance zone closely. A breakout could signal a strong move toward ₹280–₹300 by end of 2025.

Long-term investors may consider accumulating on dips near ₹200 if broader pharma sentiment supports the stock.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *